Cytel Ushers in New Era of Optimized Clinical Trial Design With Launch of Solara™

▤ Summary

Cyrus Mehta, President and Co-founder of Cytel, commented, “By illuminating the statistical design space more thoroughly, we’re enabling teams to better leverage the power of their biostatisticians for more significant business impact. Frequently, such teams lack sufficient time and resources to fully explore, compare and select the most promising design options to meet both clinical and business goals. With the highly pressured timelines that they often work towards, it’s practically impossible to explore more than a small slice of the available designs and test them for sensitivity across different clinical scenarios,” said Yannis Jemiai, Chief Scientific Officer at Cytel. The result is identification of optimal, efficient studies that can operate with fewer patients, shorter timeframes and/or higher power, while still drawing robust conclusions.” Joshua Schultz, Chief Executive Officer of Cytel, said, “Complementing the ability to more thoroughly map the statistical design space is Solara’s capacity to generate data-driven comparisons of different design options that enable product development teams and governance bodies to rapidly understand the implications of different approaches. For over thirty years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions.

▦ Linked Companies

Cytel Corporation

$10M to $25M